Rockwell Medical Inc  

(Public, NASDAQ:RMTI)   Watch this stock  
Find more results for RMTI
4.12
+0.07 (1.73%)
Jun 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.01 - 4.18
52 week 3.16 - 10.70
Open 4.14
Vol / Avg. 669,122.00/991,061.00
Mkt cap 106.54M
P/E     -
Div/yield     -
EPS -2.82
Shares 25.86M
Beta 0.83
Inst. own 30%
Aug 5, 2013
Q2 2013 Rockwell Medical Technologies Inc Earnings Release Add to calendar
May 8, 2013
Q1 2013 Rockwell Medical Technologies Inc Earnings Conference Call
May 6, 2013
Q1 2013 Rockwell Medical Technologies Inc Earnings Release
Apr 30, 2013
Rockwell Medical Technologies Inc Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -124.67% -108.38%
Operating margin -124.76% -108.87%
EBITD margin - -106.69%
Return on average assets -352.57% -220.66%
Return on average equity - -1304.38%
Employees 287 -
Carbon Disclosure Rating - -

Address

30142 Wixom Road
WIXOM, MI 48393
United States - Map
+1-248-9609009 (Phone)
+1-248-9609119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient�s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

Officers and directors

Robert L. Chioini Chairman of the Board, President, Chief Executive Officer
Portrait. Age: 47
Bio & Compensation  - Reuters
Thomas E. Klema CPA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 58
Bio & Compensation  - Reuters
Ajay Gupta M.D. Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Raymond Pratt Chief Medical Officer
Bio & Compensation  - Reuters
Patrick J. Bagley Independent Director
Age: 47
Bio & Compensation  - Reuters
Ronald D. Boyd Independent Director
Age: 49
Bio & Compensation  - Reuters
Kenneth L. Holt Independent Director
Age: 59
Bio & Compensation  - Reuters